Project details

Summary

What is the study about?

People with early AD have an abnormal protein in their brain but may or may not have some problems with their memory or thinking.

What are you trying to find out?

The purpose of this research study is to learn more about remternetug, a possible new medicine for the treatment of early Alzheimer’s disease (AD).

The study aims to learn:

• Whether remternetug can delay the start or worsening of memory and thinking problems caused by AD
• Whether remternetug works better than a placebo (a placebo is an inactive or “pretend” drug)
• The possible side effects of remternetug.

Who is it for?

This study is no longer looking for new participants but is still ongoing.

You may be able to join the research study if you:

• Are aged 55 to 80 years old
• Have no to mild issues with your memory
• Are willing to obtain a blood test as part of the study that checks whether you have an abnormal protein associated with Alzheimer’s disease and
• Have a reliable study partner. 

A study partner is a person who knows you well and would notice any changes in your memory, mood and behaviour. This could be your spouse, partner, friend, family member or someone whose job it is to help you. Your study partner would also consent to the research study.

What did taking part involve?

This study is no longer looking for new participants but is still ongoing.

If you qualify to take part in the TRAILRUNNER-ALZ 3 study, you will be randomly (that is by chance) assigned to either the investigational medicine group or the placebo group. For every 2 study participants, 1 will get investigational medicine and 1 will get placebo.

You will get an injection under the skin using a prefilled syringe. The first 5 doses will be at the clinic. The study team will give you these injections and show you how to do this. You or your study partner can give you the remaining injections at a convenient location, like at home or you can go to the clinic. If your study partner is helping you, the study team will also show them how to give the injections. 

This study will last about 5 years. It has 5 parts, including an optional extension to the study treatment period for eligible participants. After the observation period, if the investigational medicine is safe and effective, participants who received placebo may take part in the extension period and get investigational medicine. The study team will explain this to you in more detail.

During the study you will attend visits with doctors and researchers in-person at a clinic. Your study partner should come to study visits with you. If they cannot come to a visit, they should be available by phone for any questions or follow-up. They must be able to tell the research team about any changes in your memory and thinking.

Why is it important? 

Doctors and researchers are trying to find medicines that can help people with early Alzheimer’s disease. Clinical research studies like the TRAILRUNNER-ALZ 3 study are an important part of this work.

The benefits of taking part in the TRAILRUNNER-ALZ 3 study are:

• getting actively involved in healthcare research for people with Alzheimer’s disease
• helping others by advancing medical research 

If you choose to take part, you will get at no cost to you: 

• all study-related medicines 
• all study-related care and check-ins, and
• access to specialized doctors and researchers in Alzheimer’s disease

How can I find out more?

This study is no longer looking for new participants but is still ongoing.

However, if you have questions, click the button below to email the research team:

Email the research team